The rs1801131 Gene Variant and Its Impact on Health

The rs1801131 variant, also known as MTHFR A1298C, is a common genetic change in the gene that produces methylenetetrahydrofolate reductase, an enzyme involved in processing folate and regulating homocysteine levels in your body. Carrying one or two copies of this variant modestly reduces enzyme activity, but the real-world health consequences are far less dramatic than many direct-to-consumer genetic reports suggest. The picture that emerges from research is one of small, context-dependent effects that interact heavily with diet, other gene variants, and ancestry.

What rs1801131 Actually Does to the Enzyme

MTHFR converts one form of folate into another that your body uses for methylation, a chemical process involved in DNA repair, neurotransmitter production, and clearing homocysteine from your blood. The rs1801131 variant swaps a single amino acid in the regulatory domain of the enzyme, changing a glutamic acid to an alanine at position 429. This substitution sits on the protein’s surface rather than in its catalytic core, which is why its functional impact is more subtle than the better-known C677T (rs1801133) variant that sits closer to the enzyme’s active region.¹

Structural modeling shows that the amino acid swap doesn’t disrupt the hydrogen bonds holding the protein together, but it does replace a polar residue with a hydrophobic one on the protein’s surface, which can subtly change how the enzyme interacts with its surroundings and reduce its overall stability.¹ In lab studies, the variant has been shown to decrease MTHFR enzyme activity.² But this decrease is generally smaller than what you see with the C677T variant, which is why rs1801131 so often plays second fiddle in the research literature.

The Relationship With Homocysteine

One of the main reasons people care about MTHFR variants is homocysteine, an amino acid that, when elevated, has been linked to cardiovascular problems and pregnancy complications. The C677T variant is well established as a driver of higher homocysteine levels. For rs1801131, the story is muddier.

A study in a Chinese longevity cohort found that both variants were significantly associated with increased homocysteine, though through slightly different statistical patterns.³ However, a study of young adults with coronary artery disease found that while C677T carriers had significantly elevated homocysteine, the rs1801131 variant showed no such association.⁴ These conflicting findings are a pattern you’ll see throughout the rs1801131 literature: effects tend to be population-specific and can vanish when studied in a different group of people or with a different study design.

One important wrinkle is that homocysteine levels depend on far more than your MTHFR genotype. Your intake of folate, vitamin B12, and vitamin B6 all feed into the same metabolic pathway, and inadequate levels of any of them can push homocysteine up regardless of what your MTHFR gene looks like. This is part of why isolating rs1801131’s independent effect on homocysteine has been so difficult.

When Both Variants Show Up Together

Many people who discover they carry rs1801131 also carry the C677T variant, a situation called compound heterozygosity. Genotyping data from a large study found that roughly one in five people carry both the C677T and A1298C changes simultaneously.⁵ Carrying both has historically been considered more concerning than carrying either alone, because the combined burden on the enzyme could be greater.

In practice, however, compound heterozygosity for these two variants is common and usually clinically unremarkable. The genotype frequencies from population data show that carrying both changes is not rare at all, appearing in the general population at rates similar to other common genotype combinations.⁵ People who are homozygous for both variants simultaneously are extremely rare, since the two sites sit close together on the same gene and the double-homozygous combination almost never occurs on the same chromosomal copy.

Heart Disease and Myocardial Infarction

The cardiovascular research on rs1801131 is mixed but leans toward a small effect when you look at pooled data. A meta-analysis examining MTHFR polymorphisms and heart attack risk found that homozygous carriers of the rs1801131 C allele had a modestly increased risk of myocardial infarction under certain statistical models, with an odds ratio around 1.2 to 1.3.⁶ That is a real but small increase, and it was considerably weaker than the association seen with C677T in the same analysis.

Other studies complicate even this modest picture. A study examining coronary artery disease alongside fatty liver disease found no significant difference in rs1801131 genotype distribution between people with coronary artery disease and healthy controls.⁷ Meanwhile, one logistic regression analysis that looked at several gene variants together did find that mutant alleles at rs1801131 contributed to higher coronary artery disease risk, but only when considered alongside elevated homocysteine and other genetic factors.⁸ The pattern here is telling: rs1801131 on its own is a weak cardiac risk factor, but it may contribute to risk when combined with other genetic or metabolic hits.

Pregnancy Loss and Reproductive Outcomes

Recurrent pregnancy loss is one of the areas where rs1801131 has received the most attention. A meta-analysis pooling data from over 14,000 subjects found that the 1298C allele was significantly associated with increased risk of recurrent pregnancy loss, with odds ratios of roughly 1.6 in both major statistical models.⁹ But the same analysis revealed that the association was population-specific: it held strongly in Caucasian populations, where homozygous carriers had more than double the risk, but showed no significant association in East Asian populations.⁹

An earlier comprehensive meta-analysis similarly found that the maternal MTHFR A1298C polymorphism was associated with recurrent pregnancy loss under specific genetic models.¹⁰ This is one of the stronger associations in the rs1801131 literature, and it has led some clinicians to test for the variant in women with unexplained recurrent miscarriages, even though major medical guidelines have not endorsed routine screening.

On the male side, the picture is different. A large meta-analysis of MTHFR variants and male infertility found that while C677T was clearly associated with increased infertility risk, rs1801131 showed no significant association across all the studies pooled together.¹¹

Neural Tube Defects

Given that folate is critical for fetal neural tube development, researchers have naturally investigated whether rs1801131 raises the risk of defects like spina bifida. The results have been surprising. A systematic review and meta-analysis of the fetal rs1801131 genotype and neural tube defects found no significant association in the global population, and stratification by ethnicity or type of defect didn’t change the picture.¹²

In fact, one study from China went further, finding that the 1298C allele appeared to play a protective role against neural tube defect-affected pregnancy, a finding confirmed in their accompanying meta-analysis.¹³ This is in stark contrast to C677T, which was a clear risk factor in the same study. The divergence underscores that these two variants, though on the same gene, do not behave the same way in all health contexts.

Cancer Associations

The relationship between rs1801131 and cancer is one of the more genuinely interesting corners of this research, partly because the variant sometimes appears protective rather than harmful. In Lynch syndrome, a hereditary condition that strongly predisposes people to colorectal cancer, individuals carrying one or two copies of the 1298C allele had a lower risk of developing colorectal cancer than those without it. The estimated risk reduction was around 17 percent for heterozygous carriers and 22 percent for homozygous carriers. Among people with a specific mismatch repair gene mutation (MLH1), the protective effect was even stronger, with homozygous 1298C carriers seeing a roughly 39 percent lower risk.¹⁴

A broader meta-analysis of MTHFR variants and colorectal cancer in the general population similarly concluded that the 1298C allele was associated with a lower risk of colorectal cancer.¹⁵ How a variant that reduces enzyme function could protect against cancer is not fully settled, but one leading hypothesis involves the balance between DNA methylation and nucleotide synthesis. With less MTHFR activity, more folate gets shunted toward making the building blocks of DNA rather than toward methylation, which could reduce the likelihood of certain types of DNA damage that promote cancer growth.

Diet appears to modulate these associations. A study of Chinese women found that those carrying the 1298C allele who also had the highest intake of folate and riboflavin had the lowest risk of endometrial cancer, with an interaction effect that was statistically significant.¹⁶ The takeaway is that the variant’s effect on cancer risk probably depends on your nutritional context, not just on which allele you carry.

Migraine and Neurological Effects

MTHFR variants have been studied in migraine, particularly migraine with aura, because of the enzyme’s role in homocysteine metabolism and vascular function. An updated meta-analysis with trial sequential analysis found that C677T was significantly associated with migraine risk overall and with migraine with aura specifically.¹⁷ For rs1801131 alone, the evidence of an independent association with migraine is weaker. However, some researchers have reported that when both variants are present together, their joint effect on migraine susceptibility may be greater than either variant alone.¹⁸

Depression and Antidepressant Response

Depression is another condition that has been explored in connection with MTHFR, since methylation plays a role in producing neurotransmitters like serotonin and dopamine. A five-year prospective study of people with major depressive disorder found that the C677T variant was associated with how severe depression symptoms remained over time, but rs1801131 on its own showed no association with depression prognosis regardless of how it was measured.¹⁹

Where rs1801131 may matter more is in the response to antidepressant treatment. One study found that a specific MTHFR haplotype involving the normal C allele at C677T and the A allele at rs1801131 was linked to better antidepressant response, particularly in men and in people taking certain types of antidepressants.²⁰ This suggests that the variant’s relevance to mental health may lie less in causing depression and more in influencing how well particular treatments work. A review of folate-based interventions in depression noted that while both C677T and, less consistently, rs1801131 have been associated with depression susceptibility and possibly treatment resistance, current evidence does not support routine MTHFR genotyping to guide treatment decisions.²¹

Methotrexate and Drug Response

One of the most clinically concrete areas for rs1801131 is pharmacogenomics, particularly how people respond to methotrexate, a drug commonly used for rheumatoid arthritis and certain cancers. Methotrexate works partly by interfering with folate metabolism, which means MTHFR variants can influence both how well the drug works and how toxic it is.

A study of Iraqi rheumatoid arthritis patients found that people carrying at least one copy of the common allele at rs1801131 were more likely to respond to methotrexate, while those homozygous for the variant allele were more likely to be nonresponders even after adjusting for other patient and disease characteristics.²² On the toxicity side, a study of U.S. veterans with rheumatoid arthritis found that carrying even one copy of the minor allele at rs1801131 tripled the risk of significant adverse events from methotrexate, and being homozygous for the variant nearly quadrupled it.²³

These are among the strongest and most clinically actionable findings for rs1801131. If you are starting methotrexate therapy, knowing your MTHFR genotype could theoretically help your doctor anticipate whether you’ll respond well or are at higher risk for side effects, though formal pharmacogenomic guidelines for MTHFR and methotrexate are still evolving.

The Methylfolate Question

A common piece of advice circulating in wellness communities is that anyone with an MTHFR variant should take methylfolate (the active form of folate, also called 5-MTHF or L-methylfolate) instead of regular folic acid. The logic makes superficial sense: if your enzyme is less efficient at converting folic acid to its active form, skip the conversion step and take what your body actually needs.

One small clinical study in women with MTHFR mutations and recurrent pregnancy loss found that those taking methylfolate had dramatically better outcomes than those on regular folic acid, with only 16 percent experiencing miscarriage compared to 54 percent in the folic acid group.²⁴ Those numbers are striking, but this was a single small study, and it grouped together different MTHFR genotypes rather than isolating rs1801131 specifically.

For depression, the evidence points specifically toward adjunctive L-methylfolate at 15 mg per day as the most consistently supported formulation for people who haven’t responded well to antidepressants alone. Lower doses and regular folic acid have not shown consistent benefit, and a large randomized trial failed to demonstrate meaningful improvement from folic acid augmentation.²¹ Importantly, the evidence for methylfolate in depression was gathered in people with inadequate antidepressant response in general, not specifically in those with MTHFR variants.

What Medical Guidelines Actually Say

Despite the volume of research linking MTHFR variants to various conditions, major medical organizations have been clear that routine testing is not recommended. The American College of Medical Genetics and Genomics published a practice guideline stating that there is growing evidence MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of routine evaluations for blood clotting disorders.²⁵

The rise of direct-to-consumer genetic testing has put rs1801131 results in the hands of millions of people, many of whom understandably feel alarmed when their report flags an MTHFR “mutation.” But the variant is extremely common in the general healthy population, and its presence alone, without documented elevated homocysteine or another clinical problem, is not considered an indication for treatment or specialized workup by major medical societies.²⁶ The disconnect between the anxiety these results generate and the limited clinical action they warrant is one of the bigger practical problems in consumer genomics today.

Skin Pigmentation and Evolutionary Context

One of the more unexpected threads in MTHFR research involves the relationship between folate-related gene variants and skin color. Folate is broken down by ultraviolet radiation, and darker skin pigmentation protects against folate degradation. A study examining the frequency of folate-related polymorphisms across populations with different skin pigmentation found novel relationships between skin color and folate gene variants, with trends suggesting that these genotypes are shaped by natural selection to maintain folate balance under varying UV exposure.²⁷ This helps explain why the frequency of rs1801131 and other MTHFR variants differs so widely across ethnic groups, and why the health effects of these variants are so often population-specific. The variant isn’t simply “good” or “bad” in some universal sense; its impact depends on the dietary and environmental context a population has historically adapted to.

A case-control study in Saudi Arabia illustrated this nicely, finding that carriers of the rs1801131 variant allele actually had substantially lower risks of smoking-related disease compared to those with the common genotype.²⁸ That protective effect among smokers, combined with the protective effects seen in colorectal cancer and neural tube defects, reinforces that rs1801131 does not fit neatly into a “harmful variant” box. Its consequences depend on which tissue you’re looking at, what else is in the diet, what other genes are doing, and which population is being studied.

DNA Stability and Methylation

Given that MTHFR variants affect folate metabolism, you might expect them to leave clear fingerprints on DNA itself, perhaps through altered methylation patterns or increased DNA damage. A study that directly measured DNA strand breaks, misincorporated uracil (a marker of impaired DNA repair), and global DNA methylation status in people carrying either MTHFR variant found no significant associations for either rs1801131 or C677T with any of these DNA stability markers.²⁹ This is a genuinely important negative finding. It suggests that whatever health effects rs1801131 has, they probably don’t operate through wholesale disruption of DNA integrity or global methylation, at least not in people with adequate folate intake. The mechanism linking the variant to disease may be more about local or tissue-specific metabolic shifts than about a generalized breakdown in DNA maintenance.

1
Scientific Reports. Genetic association and computational analysis of MTHFR gene polymorphisms rs1801131 and rs1801133 with breast cancer in the Bangladeshi population
2
PubMed. Quantitative assessment of the association between MTHFR rs1801131 polymorphism and risk of liver cancer
3
The Journal of nutrition, health and aging. Genetic Variants of Homocysteine Metabolism, Homocysteine, and Frailty – Rugao Longevity and Ageing Study
4
PubMed Central. Association of MTHFR C677T (rs1801133) and A1298C (rs1801131) Polymorphisms with Serum Homocysteine, Folate and Vitamin B12 in Patients with Young Coronary Artery Disease
5
Genetics in Medicine. Detection of 677CT/1298AC “double variant” chromosomes: Implications for interpretation of MTHFR genotyping results
6
PubMed Central. MTHFR gene polymorphisms and susceptibility to myocardial infarction: Evidence from meta-analysis and trial sequential analysis
7
Gene Expression. Methylenetetrahydrofolate Reductase Gene rs1801131 and rs1801133 Polymorphisms were Associated with Susceptibility to Coronary Artery Disease and Nonalcoholic Fatty Liver Disease
8
PubMed. The communal relation of MTHFR, MTR, ACE gene polymorphisms and hyperhomocysteinemia as conceivable risk of coronary artery disease
9
PubMed. MTHFR 1298A>C Substitution is a Strong Candidate for Analysis in Recurrent Pregnancy Loss: Evidence from 14,289 Subjects
10
PubMed. Association between maternal, fetal and paternal MTHFR gene C677T and A1298C polymorphisms and risk of recurrent pregnancy loss: a comprehensive evaluation
11
PubMed Central. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and male infertility risk: An updated meta-analysis
12
PubMed. Association between Fetal MTHFR A1298C (rs1801131) Polymorphism and Neural Tube Defects Risk: A Systematic Review and Meta-Analysis
13
PubMed. Variants in MTHFR gene and neural tube defects susceptibility in China
14
Scientific Reports. MTHFR C677T and A1298C polymorphism’s effect on risk of colorectal cancer in Lynch syndrome
15
PubMed Central. Association of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with colorectal cancer risk: A meta-analysis
16
Cancer Epidemiology, Biomarkers & Prevention. Dietary Folate Intake, MTHFR Genetic Polymorphisms, and the Risk of Endometrial Cancer among Chinese Women
17
PubMed. A Comprehensive Investigation into the Association Between Mthfr C677t, A1298c, and Ace I/D Variants and Risk of Migraine: an Updated Meta-Analysis of Genetic Association Studies with Trial Sequential Analysis and Meta-Regression
18
Archives of Medical Laboratory Sciences. MTHFR Gene Polymorphisms and Susceptibility to Migraine Attacks
19
PubMed. Methylenetetrahydrofolate reductase (MTHFR) genetic variation and major depressive disorder prognosis: A five-year prospective cohort study of primary care attendees
20
PubMed Central. Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response
21
International Journal of Biological and Biomedical Research. Folate-Based Interventions in Major Depressive Disorder: From Folic Acid and L-Methylfolate to MTHFR and Precision Psychiatry
22
Scientific Reports. Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients
23
PubMed Central. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis
24
Open Journal of Obstetrics and Gynecology. Comparative Study between the Use of Regular Folic Acid Supplement versus the Use of L-Methyl Folate in Patients with Methyl Tetrahydrofolate Reductase (MTHFR) Gene Mutation with Recurrent Pregnancy Loss
25
Genetics in Medicine. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing
26
PubMed Central. MTHFR genetic testing: is there a clinical utility?
27
PubMed. Frequency of folate-related polymorphisms varies by skin pigmentation
28
Genetics in Medicine. The protective effects of the methylenetetrahydrofolate reductase rs1801131 variant among Saudi smokers
29
Cancer Epidemiology, Biomarkers & Prevention. Associations between Two Common Variants C677T and A1298C in the Methylenetetrahydrofolate Reductase Gene and Measures of Folate Metabolism and DNA Stability (Strand Breaks, Misincorporated Uracil, and DNA Methylation Status) in Human Lymphocytes In vivo